WHITEHAWK THERAPEUTICS, INC. Investment Income, Interest
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Investment Income, Interest of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $1.48M, a 25.47% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $1.33M, a 67.89% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $1.61M, a 138.31% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $1.85M, a 104.19% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for fiscal 2025 was $6.23M, a 58.75% increase from fiscal 2024.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $3.92M, a 38.67% decline from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $6.40M, a 166.89% increase from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. investment income, interest for fiscal 2022 was $2.40M, a 18346.15% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-08-06 | $2.80M 10-Q · filed 2026-08-06 | $4.41M derived: sum of 3 quarters · filed 2026-08-06 | $6.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-07 | $2.94M derived: sum of 2 quarters · filed 2026-05-07 | $4.79M derived: sum of 3 quarters · filed 2026-05-07 | $6.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.46M derived: sum of 2 quarters · filed 2026-03-12 | $5.44M derived: sum of 3 quarters · filed 2026-08-06 | $6.23M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.85M 10-Q · filed 2025-11-06 | $3.83M derived: sum of 2 quarters · filed 2026-08-06 | $4.62M 10-Q · filed 2025-11-06 | $5.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.98M 10-Q · filed 2026-08-06 | $2.77M 10-Q · filed 2026-08-06 | $3.45M derived: sum of 3 quarters · filed 2026-08-06 | $4.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $791.00K 10-Q · filed 2026-05-07 | $1.47M derived: sum of 2 quarters · filed 2026-05-07 | $2.37M derived: sum of 3 quarters · filed 2026-05-07 | $3.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $676.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.58M derived: sum of 2 quarters · filed 2026-03-12 | $2.64M derived: sum of 3 quarters · filed 2026-03-12 | $3.92M 10-K · filed 2026-03-12 |
| 2024-09-30 | $906.00K 10-Q · filed 2025-11-06 | $1.97M derived: sum of 2 quarters · filed 2025-11-06 | $3.25M 10-Q · filed 2025-11-06 | $4.75M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.06M 10-Q · filed 2025-08-07 | $2.34M 10-Q · filed 2025-08-07 | $3.84M derived: sum of 3 quarters · filed 2025-08-07 | $5.45M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-08 | $2.78M derived: sum of 2 quarters · filed 2025-05-08 | $4.39M derived: sum of 3 quarters · filed 2025-05-08 | $6.02M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $3.10M derived: sum of 2 quarters · filed 2025-03-28 | $4.74M derived: sum of 3 quarters · filed 2025-03-28 | $6.40M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.60M 10-Q · filed 2024-11-06 | $3.24M derived: sum of 2 quarters · filed 2024-11-06 | $4.90M 10-Q · filed 2024-11-06 | $6.51M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.64M 10-Q · filed 2024-08-07 | $3.29M 10-Q · filed 2024-08-07 | $4.90M derived: sum of 3 quarters · filed 2024-08-07 | $5.52M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $1.66M 10-Q · filed 2024-05-08 | $3.27M derived: sum of 2 quarters · filed 2024-05-08 | $3.89M derived: sum of 3 quarters · filed 2024-05-08 | $4.04M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $2.23M derived: sum of 2 quarters · filed 2024-03-13 | $2.38M derived: sum of 3 quarters · filed 2024-03-13 | $2.40M 10-K · filed 2024-03-13 |
| 2022-09-30 | $620.00K 10-Q · filed 2023-11-08 | $778.00K derived: sum of 2 quarters · filed 2023-11-08 | $791.00K 10-Q · filed 2023-11-08 | $805.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $158.00K 10-Q · filed 2023-08-09 | $171.00K 10-Q · filed 2023-08-09 | $185.00K derived: sum of 3 quarters · filed 2023-08-09 | $185.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $15.00K 10-Q · filed 2023-05-10 | $27.00K derived: sum of 2 quarters · filed 2023-05-10 | $27.00K derived: sum of 3 quarters · filed 2023-05-10 | $28.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $12.00K derived: sum of 2 quarters · filed 2023-03-29 | $13.00K derived: sum of 3 quarters · filed 2023-03-29 | $13.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $1.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-10 | $1.00K 10-Q · filed 2022-08-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.00K derived: sum of 2 quarters · filed 2022-03-17 | $41.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | $41.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |